⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 12, 2024World Journal of Gastrointestinal OncologyOpen Access

Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma

Brendha Cação Coimbra Marina Alessandra Pereira Leonardo Cardili Venâncio Avancini Ferreira Alves Evandro Sobroza de Mello Ulysses Ribeiro Marcus Fernando Kodama Pertille Ramos

View Full Paper

Ask AI

Bookmark

Share

Abstract

Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has demonstrated promising results on gastric cancer (GC). However, PD-L1 can express differently between metastatic sites and primary tumors (PT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coimbra et al. (2024) studied this question.

synapsesocial.com/papers/68e745c5b6db6435876bf38f https://doi.org/10.4251/wjgo.v16.i3.883

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Correlation of tumor-infiltrating lymphocyte score with programmed death ligand-1 expression in gastric adenocarcinoma2025
2Programmed death-ligand 1 (PD-L1) expression in various tumor typesOriginal Research · 2013 · 29 citations
3Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art2024 · 14 citations
4Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma2024 · 17 citations
5Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists2024 · 13 citations